FOXP3 and neoplasm: The loss of SCAP in tumor Tregs has been shown to increase the proportion of CD8+ T cells and Foxp3-CD4+ T cells in the TME, to inhibit tumor growth and to enhance anti-PD-1 immunotherapy.